本周推荐
2018年SCI影响因子排名首位的《CA: a cancer journal for clinicians》，影响因子为：244.585。
本期内容着重分析其2013-2018年期刊发文的主题趋势以及2018年发表的精选文献五篇与大家分享，欢迎大家阅读。
如大家有感兴趣的期刊，请于文章下方留言给小编~~~
2013-2018年《CA: a cancer journal for clinicians》发表文献
主题词Top10统计
数据来源：万方医学网收录2013-2018年CA: a cancer journal for clinicians发表文章。
2013-2018年《CA: a cancer journal for clinicians》发表文献
关键词Top10统计
数据来源：万方医学网收录2013-2018年CA: a cancer journal for clinicians发表文章。
2018年该刊发表文献推荐
2018年美国癌症协会总结更新了美国癌症协会结直肠癌筛查指南并对2013年肺癌筛查指南的语言进行了澄清。
Cancer screening in the United States, 2018: A review of current American Cancer Society guidelines and current issues in cancer screening.
摘要：
Each year, the American Cancer Society publishes a summary of its guidelines for early cancer detection, data and trends in cancer screening rates from the National Health Interview Survey, and select issues related to cancer screening. In this 2018 update, we also summarize the new American Cancer Society colorectal cancer screening guideline and include a clarification in the language of the 2013 lung cancer screening guideline. CA Cancer J Clin 2018. © 2018 American Cancer Society.
作者：Robert A, Smith ; Kimberly S, Andrews ; Durado, Brooks ; Stacey A, Fedewa ; Deana, Manassaram-Baptiste ; Debbie, Saslow ; Otis W, Brawley ; Richard C, Wender
期刊：《CA: a cancer journal for clinicians》
美国癌症协会（ACS）于2018年更新了针对普通成年人的结肠直肠癌筛查指南，对于本指南更新，使用了现有的CRC筛查文献和微观模拟建模分析的系统性证据回顾。
Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society.
摘要：
In the United States, colorectal cancer (CRC) is the fourth most common cancer diagnosed among adults and the second leading cause of death from cancer. For this guideline update, the American Cancer Society (ACS) used an existing systematic evidence review of the CRC screening literature and microsimulation modeling analyses, including a new evaluation of the age to begin screening by race and sex and additional modeling that incorporates changes in US CRC incidence. Screening with any one of multiple options is associated with a significant reduction in CRC incidence through the detection and removal of adenomatous polyps and other precancerous lesions and with a reduction in mortality through incidence reduction and early detection of CRC. Results from modeling analyses identified efficient and model-recommendable strategies that started screening at age 45 years. The ACS Guideline Development Group applied the Grades of Recommendations, Assessment, Development, and Evaluation (GRADE) criteria in developing and rating the recommendations. The ACS recommends that adults aged 45 years and older with an average risk of CRC undergo regular screening with either a high-sensitivity stool-based test or a structural (visual) examination, depending on patient preference and test availability. As a part of the screening process, all positive results on noncolonoscopy screening tests should be followed up with timely colonoscopy. The recommendation to begin screening at age 45 years is a qualified recommendation. The recommendation for regular screening in adults aged 50 years and older is a strong recommendation. The ACS recommends (qualified recommendations) that: 1) average-risk adults in good health with a life expectancy of more than 10 years continue CRC screening through the age of 75 years; 2) clinicians individualize CRC screening decisions for individuals aged 76 through 85 years based on patient preferences, life expectancy, health status, and prior screening history; and 3) clinicians discourage individuals older than 85 years from continuing CRC screening. The options for CRC screening are: fecal immunochemical test annually; high-sensitivity, guaiac-based fecal occult blood test annually; multitarget stool DNA test every 3 years; colonoscopy every 10 years; computed tomography colonography every 5 years; and flexible sigmoidoscopy every 5 years. CA Cancer J Clin 2018;000:000-000. © 2018 American Cancer Society.
作者：Andrew M D, Wolf ; Elizabeth T H, Fontham ; Timothy R, Church ; Christopher R, Flowers ; Carmen E, Guerra ; Samuel J, LaMonte ; Ruth, Etzioni ; Matthew T, McKenna ; Kevin C, Oeffinger ; Ya-Chen Tina, Shih ; Louise C, Walter ; Kimberly S, Andrews ; Otis W, Brawley ; Durado, Brooks ; Stacey A, Fedewa ; Deana, Manassaram-Baptiste ; Rebecca L, Siegel ; Richard C, Wender ; Robert A, Smith
期刊：《CA: a cancer journal for clinicians》
在2018年，美国预计将诊断出卵巢癌新增病例大约22,240例，预计卵巢癌死亡病例大约14070例。在此，美国癌症协会根据全国人口癌症登记处的发病率数据和国家卫生统计中心的死亡率数据，概述了卵巢癌的发生情况，并审查了早期检测策略的状态。
Ovarian cancer statistics, 2018.
摘要：
In 2018, there will be approximately 22,240 new cases of ovarian cancer diagnosed and 14,070 ovarian cancer deaths in the United States. Herein, the American Cancer Society provides an overview of ovarian cancer occurrence based on incidence data from nationwide population-based cancer registries and mortality data from the National Center for Health Statistics. The status of early detection strategies is also reviewed. In the United States, the overall ovarian cancer incidence rate declined from 1985 (16.6 per 100,000) to 2014 (11.8 per 100,000) by 29% and the mortality rate declined between 1976 (10.0 per 100,000) and 2015 (6.7 per 100,000) by 33%. Ovarian cancer encompasses a heterogenous group of malignancies that vary in etiology, molecular biology, and numerous other characteristics. Ninety percent of ovarian cancers are epithelial, the most common being serous carcinoma, for which incidence is highest in non-Hispanic whites (NHWs) (5.2 per 100,000) and lowest in non-Hispanic blacks (NHBs) and Asians/Pacific Islanders (APIs) (3.4 per 100,000). Notably, however, APIs have the highest incidence of endometrioid and clear cell carcinomas, which occur at younger ages and help explain comparable epithelial cancer incidence for APIs and NHWs younger than 55 years. Most serous carcinomas are diagnosed at stage III (51%) or IV (29%), for which the 5-year cause-specific survival for patients diagnosed during 2007 through 2013 was 42% and 26%, respectively. For all stages of epithelial cancer combined, 5-year survival is highest in APIs (57%) and lowest in NHBs (35%), who have the lowest survival for almost every stage of diagnosis across cancer subtypes. Moreover, survival has plateaued in NHBs for decades despite increasing in NHWs, from 40% for cases diagnosed during 1992 through 1994 to 47% during 2007 through 2013. Progress in reducing ovarian cancer incidence and mortality can be accelerated by reducing racial disparities and furthering knowledge of etiology and tumorigenesis to facilitate strategies for prevention and early detection. CA Cancer J Clin 2018. © 2018 American Cancer Society.
作者：Lindsey A, Torre ; Britton, Trabert ; Carol E, DeSantis ; Kimberly D, Miller ; Goli, Samimi ; Carolyn D, Runowicz ; Mia M, Gaudet ; Ahmedin, Jemal ; Rebecca L, Siegel
期刊：《CA: a cancer journal for clinicians》
在这篇综述中，作者通过总结控制疼痛的重要性、充分疼痛管理的障碍、评估和管理癌症相关疼痛的策略、如何管理患者的疼痛的证据，提供了安全有效地管理癌症相关疼痛的框架。
Optimal pain management for patients with cancer in the modern era.
摘要：
Pain is a common symptom among patients with cancer. Adequate pain assessment and management are critical to improve the quality of life and health outcomes in this population. In this review, the authors provide a framework for safely and effectively managing cancer-related pain by summarizing the evidence for the importance of controlling pain, the barriers to adequate pain management, strategies to assess and manage cancer-related pain, how to manage pain in patients at risk of substance use disorder, and considerations when managing pain in a survivorship population. CA Cancer J Clin 2018;68:182-196. © 2018 American Cancer Society.
作者：Bethann M, Scarborough ; Cardinale B, Smith
期刊：《CA: a cancer journal for clinicians》 2018年68卷3期182-196页
PROSPR联盟的系统评价综述评估了已发表的关于乳腺癌、宫颈癌、结肠直肠癌和肺癌的阳性筛查后随访时间的研究。关于及时随访阳性癌症筛查结果表示，对阳性癌症筛查结果的及时随访仍然不理想，并且提供关于优化诊断测试的及时性的决策的证据基础还不清楚。
Timely follow-up of positive cancer screening results: A systematic review and recommendations from the PROSPR Consortium.
摘要：
Timely follow-up for positive cancer screening results remains suboptimal, and the evidence base to inform decisions on optimizing the timeliness of diagnostic testing is unclear. This systematic review evaluated published studies regarding time to follow-up after a positive screening for breast, cervical, colorectal, and lung cancers. The quality of available evidence was very low or low across cancers, with potential attenuated or reversed associations from confounding by indication in most studies. Overall, evidence suggested that the risk for poorer cancer outcomes rises with longer wait times that vary within and across cancer types, which supports performing diagnostic testing as soon as feasible after the positive result, but evidence for specific time targets is limited. Within these limitations, we provide our opinion on cancer-specific recommendations for times to follow-up and how existing guidelines relate to the current evidence. Thresholds set should consider patient worry, potential for loss to follow-up with prolonged wait times, and available resources. Research is needed to better guide the timeliness of diagnostic follow-up, including considerations for patient preferences and existing barriers, while addressing methodological weaknesses. Research is also needed to identify effective interventions for reducing wait times for diagnostic testing, particularly in underserved or low-resource settings. CA Cancer J Clin 2018;68:199-216. © 2018 American Cancer Society.
作者：Chyke A, Doubeni ; Nicole B, Gabler ; Cosette M, Wheeler ; Anne Marie, McCarthy ; Philip E, Castle ; Ethan A, Halm ; Mitchell D, Schnall ; Celette S, Skinner ; Anna N A, Tosteson ; Donald L, Weaver ; Anil, Vachani ; Shivan J, Mehta ; Katharine A, Rendle ; Stacey A, Fedewa ; Douglas A, Corley ; Katrina, Armstrong
期刊：《CA: a cancer journal for clinicians》 2018年68卷3期199-216页
